Gene Therapy Showing Promise in Fighting Melanoma
Article originally published in September, 1999
MADISON - In treating dogs for a highly aggressive form of melanoma,
a University of Wisconsin-Madison research team is having success with a
new cancer vaccine that could benefit human cancer-fighting efforts.
Professor Gregory MacEwen and research scientist Gary Hogge, of the UW-Madison
School of Veterinary Medicine, have developed a method of gene therapy that
helps the animal's immune system recognize and attack cancer cells. In the
September issue of the journal Human Gene Therapy, the researchers reported
the vaccine helped some animals live longer and shrunk the tumor in about
20 percent of animals treated.
"This is important work with melanoma, because there currently are
no other treatment alternatives," said MacEwen. "Melanoma is resistant
to chemotherapy drugs, and surgery doesn't always help because melanoma's
spread is so aggressive. We're trying to establish this as a standard of
care."
The study details the treatment of 16 dogs that had advanced stages of
melanoma that could not be successfully treated through surgery or drugs.
The cases were referred to the UW-Madison school by veterinarians from around
the country.
To develop the vaccine, the researchers began by surgically removing
as much of the tumor as possible. They extracted and purified individual
cells from the tumor and injected DNA into those cells that accelerated
production of chemicals called cytokines. Cytokine molecules stimulate production
of certain white blood cells in the body. The altered cells are then injected
back into patients in the form of a vaccine.
The vaccine is administered with a "gene gun," a unique tool
that helps scientists insert genetic material into cells. With air pressure,
the gun can shoot millions of microscopic gold beads coated with DNA into
cells, which are then injected back into the patient. In cells that are
penetrated by the beads, the new genetic material becomes integrated into
the cell and the cytokine is produced.
With this therapy, the animal's immune response is improved by the increase
in cytokine production. The cytokines "train" the immune system
to recognize and kill tumor cells, Hogge said.
Cancer vaccines and gene therapy, which have become widely studied in
the past decade, could provide a new approach to fighting cancer with fewer
side effects than chemotherapy or radiation therapy. This study is unique,
Hogge said, because the gene therapy can produce a broad range of immune
responses against surviving tumor cells in the patient.
"This is a way to trick the immune system and get the body to fight
the tumor," Hogge said.
MacEwen said this study closely parallels work in human gene therapy
to treat cancer, and provides additional information that benefits those
projects. "We try to target a lot of the research we do so it will
benefit the development and design of human clinical trials," he said.
Dogs provide a good model for understanding cancer in humans, MacEwen
said, because of their large size and biological similarity. The causes
and behaviors of cancers in humans and dogs are also very similar.
Melanoma is a common type of oral cancer in dogs. While oral melanoma
is rare in humans, there are roughly 35,000 cases of melanoma skin cancer
reported in America each year, and it remains one of the deadliest forms
of cancer because of its ability to spread rapidly, MacEwen said.
### - Brian Mattmiller, (608) 262-9772 |